Patent · US Active

Baclofen formulations and methods of minimizing patient exposure to metabolite variations

US11850225B2 · kind B2 · utility

0Cited by

1References

19Claims

0Family size

Assignee

AMNEAL PHARMACEUTICALS LLC · US

Inventors

Leonard O'Mahony · Mullingar, IE
Sharon Hamm · Land O' Lakes, US
John Devane · Dublin, IE
David Penake · San Francisco, US
Wolfgang Mohr · Freiburg (Elbe), DE
Manuel Weinheimer · Neustadt an der Weinstraße, DE

Key dates

Filing date	Jul 11, 2022
Grant date	Dec 26, 2023
Priority date	—
Expiry date	Jul 11, 2042

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K31/197
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Baclofen formulations, including formulations that minimize variability between doses, that minimize variation in patient exposure baclofen metabolites, and are bioequivalent in regards to baclofen versus M1 metabolite ratios of baclofen tablets.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.